Jürg Meyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jürg Meyer has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Helen Kovari
Center for Infectious Diseases, Hirslanden Klinik im Park
1 shared publication - Maria Dg de Melo Oliveira
Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
1 shared publication - Paula Hauser
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
1 shared publication - Rainer Weber
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
1 shared publication - Reinhard Zbinden
Institute of Medical Microbiology, University of Zurich, 8006 Zurich, Switzerland
1 shared publication - Severin Läuchli
University Hospital Zürich
1 shared publication
Latest Publications
- Open Access
- 26 December 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 603
Decreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012
Neisseria gonorrhoeae can rapidly develop resistance to antimicrobial agents. Over the last years, decreased gonococcal susceptibility to third-generation cephalosporins, especially cefixime, emerged worldwide. Therefore, current international guidelines recommend dual therapy for gonorrhoea with ceftriaxone plus either azithromycin or doxycycline. Gonococcal susceptibility data in Switzerland are sparse.
- 26 December 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 603
Open AccessDecreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012
Neisseria gonorrhoeae can rapidly develop resistance to antimicrobial agents. Over the last years, decreased gonococcal susceptibility to third-generation cephalosporins, especially cefixime, emerged worldwide. Therefore, current international guidelines recommend dual therapy for gonorrhoea with ceftriaxone plus either azithromycin or doxycycline. Gonococcal susceptibility data in Switzerland are sparse.